# Nautilus Biotechnology, Inc.: overview NAUT · Nasdaq · CIK 1808805 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/naut.md) · [Financials](/companies/naut/financials.md) · [Filings](/companies/naut/filings.md) · [Insiders](/companies/naut/insiders.md) Latest reported revenue: [$234.0k](/filings/0001808805-26-000052.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 27, 2026 (XBRL us-gaap:Revenues, accession 0001808805-26-000052). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001808805-26-000034.md) | [0.0](/filings/0001808805-26-000052.md) | not reported | not reported | [0.2](/filings/0001808805-26-000034.md) | [0.2](/filings/0001808805-26-000052.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(7615.3%)](/filings/0001808805-26-000034.md) | [(6682.1%)](/filings/0001808805-26-000052.md) | | Diluted EPS | $ per share | not reported | [(0.13)](/filings/0001808805-26-000022.md) | [(0.12)](/filings/0001808805-26-000034.md) | [(0.11)](/filings/0001808805-26-000052.md) | not reported | [(0.12)](/filings/0001808805-26-000022.md) | [(0.11)](/filings/0001808805-26-000034.md) | [(0.12)](/filings/0001808805-26-000052.md) | | Free cash flow | $m | [(14.6) d](/filings/0001808805-26-000011.md) | [(14.2)](/filings/0001808805-26-000022.md) | [(13.7) d](/filings/0001808805-26-000034.md) | [(11.5) d](/filings/0001808805-26-000052.md) | [(12.6) d](/filings/0001808805-26-000011.md) | [(13.6)](/filings/0001808805-26-000022.md) | [(14.2) d](/filings/0001808805-26-000034.md) | [(14.7) d](/filings/0001808805-26-000052.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.60)](/filings/0001808805-23-000011.md) | [(0.46)](/filings/0001808805-24-000005.md) | [(0.51)](/filings/0001808805-25-000008.md) | [(0.56)](/filings/0001808805-26-000011.md) | [(0.47)](/filings/0001808805-26-000011.md) | | Free cash flow | $m | [(41.5)](/filings/0001808805-23-000011.md) | [(48.1)](/filings/0001808805-24-000005.md) | [(54.2)](/filings/0001808805-25-000008.md) | [(61.3)](/filings/0001808805-26-000011.md) | [(52.0)](/filings/0001808805-26-000011.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/naut/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $21.8m | 11,634,211 | | Reduced −960,000 | | [a16z Capital Management, L.L.C.](/funds/1540358.md) | 2026-06-30 | $16.9m | 9,063,054 | | Reduced −8,590,863 | | [Cercano Management LLC](/funds/1936416.md) | 2026-06-30 | $13.4m | 7,172,985 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.0m | 2,687,226 | | Added +2,499,555 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.8m | 2,549,979 | | Added +4,382 | | [Comprehensive Financial Management LLC](/funds/1799802.md) | 2026-06-30 | $4.1m | 2,207,619 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $3.5m | 1,896,192 | | New +1,896,192 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.4m | 1,265,535 | | Added +662,011 | | [Clearstead Advisors, LLC](/funds/842775.md) | 2026-06-30 | $1.7m | 892,787 | | Reduced −1,436,997 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.7m | 890,949 | | New +890,949 | ## Recent filings [All 327 filings](/companies/naut/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 07:37 ET | [10-Q](/filings/0001808805-26-000052.md) | Quarterly report, period 2026-09-30 | 0001808805-26-000052 | | 2026-10-27 | 18:46 ET | [8-K](/filings/0001808805-26-000049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001808805-26-000049 | | 2026-09-11 | 17:08 ET | [SCHEDULE 13D/A](/filings/0001231919-26-001165.md) | Ownership report, active investor, amended | 0001231919-26-001165 | | 2026-09-11 | 16:08 ET | [8-K](/filings/0001808805-26-000041.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001808805-26-000041 | | 2026-08-28 | 19:43 ET | [SCHEDULE 13D/A](/filings/0001725721-26-000006.md) | Ownership report, active investor, amended | 0001725721-26-000006 | | 2026-08-14 | 17:20 ET | [SCHEDULE 13D/A](/filings/0001193125-26-352644.md) | Ownership report, active investor, amended | 0001193125-26-352644 | | 2026-07-28 | 16:06 ET | [10-Q](/filings/0001808805-26-000034.md) | Quarterly report, period 2026-06-30 | 0001808805-26-000034 | | 2026-07-28 | 19:29 ET | [8-K](/filings/0001808805-26-000030.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001808805-26-000030 | | 2026-06-30 | 17:13 ET | [SCHEDULE 13D/A](/filings/0001725721-26-000004.md) | Ownership report, active investor, amended | 0001725721-26-000004 | | 2026-06-18 | 16:05 ET | [8-K](/filings/0001808805-26-000027.md) | 5.07 Shareholder vote results | 0001808805-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001808805-26-000011.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/44babce1-abe8-409c-b847-3baee4a63923) ## About the filer - CIK: 1808805 - Tickers: NAUT - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:43 ET. No prices; not investment advice.